

Supplementary Table 3. Individual data for participants before and after treatment with the photobiomodulation protocols.

	GROUP AA PARTICIPANTS						GROUP AB PARTICIPANTS					
	AA1	AA2	AA3	AA4	AA5	AA6	AB1	AB2	AB3	AB4	AB5	AB6
NHPT (seconds)												
affected hand												
12 weeks prior to treatment							29.0	45.8	19.6	25.1	21.0	24.0
immediately before treatment	22.5	23.0	21.2	26.1	21.5	21.6	22.2 (23%)	56.5 (-23%)	19.5 (1%)	31.3 (-24%)	22.3 (-6%)	22.8 (5%)
after 4 weeks treatment (CT)							25.8 (11%)	48.2 (-5%)	21.5 (-10%)	25.7 (-2%)	22.3 (-6%)	19.2 (20%)
after 12 weeks treatment (CT)	21.1 (6%)	28.6 (-24%)	28.0 (-32%)	37.1 (-42%)	17.9 (17%)	27.1 (-25%)	27.9 (4%)	47.6 (-4%)	20.5 (-4%)	34.8 (-38%)	24.1 (-15%)	23.2 (3%)
after 26/38 week home treatm	21.8 (3%)			27.3 (-5%)	21.6 (0%)	29.6 (-37%)	29.4 (-1%)	69.9 (-53%)	22.0 (-12%)	23.4 (7%)	16.4 (22%)	24.4 (-2%)
dominant hand												
12 weeks prior to treatment							20.1	30.2	19.6	24.1	21.9	24.0
immediately before treatment	29.3	18.1	33.7	26.4	16.0	25.7	18.0 (11%)	29.1 (4%)	19.5 (1%)	26.6 (-10%)	17.9 (18%)	22.8 (5%)
after 4 weeks treatment (CT)							16.5 (18%)	24.9 (18%)	21.5 (-10%)	26.8 (-11%)	18.7 (15%)	19.2 (20%)
after 12 weeks treatment (CT)	25.8 (12%)	17.9 (1%)	27.7 (18%)	26.8 (-2%)	17.7 (-10%)	20.0 (22%)	25.5 (-27%)	28.3 (6%)	20.5 (-4%)	28.8 (-20%)	20.1 (8%)	23.2 (3%)
after 26/38 week home treatm	21.8 (26%)			27.9 (-6%)	17.0 (-6%)	27.1 (-5%)	17.1 (15%)	29.6 (2%)	20.1 (-2%)	28.8 (-20%)	21.4 (2%)	22.5 (6%)
SPIRAL TEST (seconds)												
dominant hand												
12 weeks prior to treatment							32.4	37.5	48.6	33.9	29.3	36.5
immediately before treatment	20.4	23.8	29.3	52.5	22.6	26.2	29.6 (9%)	38.2 (-2%)	28.7 (41%)	42.0 (-24%)	20.7 (29%)	40.3 (-10%)
after 4 weeks treatment (CT)							19.4 (40%)	30.8 (18%)	18.7 (61%)	41.7 (-23%)	23.7 (19%)	31.2 (15%)
after 12 weeks treatment (CT)	16.8 (18%)	23.7 (0%)	31.9 (-9%)	23.2 (56%)	16.5 (27%)	21.1 (19%)	28.9 (11%)	29.9 (20%)	29.1 (40%)	45.9 (-35%)	14.1 (52%)	21.7 (41%)
after 26/38 week home treatm	17.8 (13%)	27.6 (-16%)		44.2 (16%)	17.4 (23%)	14.9 (43%)	34.4 (-6%)	34.2 (9%)	19.8 (59%)	35.9 (-6%)	21.1 (28%)	27.9 (24%)
STEP TEST (number of steps)												
affected foot												
12 weeks prior to treatment							17	11	14	9	9	7
immediately before treatment	12	12	8	14	18	14	21 (24%)	12 (9%)	15 (7%)	13 (44%)	13 (44%)	15 (114%)
after 4 weeks treatment (CT)							23 (35%)	14 (27%)	17 (21%)	15 (67%)	15 (67%)	14 (100%)
after 12 weeks treatment (CT)	15 (25%)	18 (50%)	11 (38%)	20 (43%)	23 (28%)	17 (21%)	23 (35%)	14 (27%)	19 (36%)	11 (22%)	16 (78%)	15 (114%)
after 26/38 week home treatm	15 (25%)	nd	nd	18 (29%)	21 (17%)	17 (21%)	20 (18%)	12 (9%)	21 (50%)	11 (22%)	18 (100%)	14 (100%)
dominant foot												
12 weeks prior to treatment							12	10	14	11	12	7
immediately before treatment	12	11	9	12	20	14	18 (50%)	12 (20%)	15 (7%)	11 (0%)	12 (0%)	15 (114%)
after 4 weeks treatment (CT)							21 (75%)	12 (20%)	17 (21%)	15 (36%)	15 (25%)	14 (100%)
after 12 weeks treatment (CT)	14 (17%)	18 (64%)	11 (22%)	16 (33%)	22 (10%)	17 (21%)	21 (75%)	12 (20%)	19 (36%)	13 (18%)	17 (42%)	15 (114%)
after 26/38 week home treatm	14 (17%)	nd	nd	20 (67%)	21 (5%)	17 (21%)	24 (100%)	13 (30%)	21 (50%)	13 (18%)	19 (58%)	14 (100%)
TS (seconds)												
affected foot behind												
12 weeks prior to treatment							8.0	0.0	2.0	4.0	2.0	0.0
immediately before treatment	30.0	12.0	0.0	0.0	1.0	6.0	8.0 (0%)	1.0	7.5 (275%)	14.0 (250%)	3.6 (80%)	0.0
after 4 weeks treatment (CT)							30.0 (275%)	4.7	30.0 (1400%)	30.0 (650%)	9.0 (350%)	2.7
after 12 weeks treatment (CT)	30.0	30.0 (150%)	9.5	0.0	2.0 (100%)	2.0 (-67%)	15.0 (88%)	1.0	5.6 (180%)	30.0 (650%)	6.0 (200%)	1.0
after 26/38 week home treatm	30.0	nd	nd	0.0	4.0 (300%)	3.9 (-34%)	30.0 (275%)	nd	30.0 (1400%)	3.9 (-2%)	3.4 (70%)	3.0
unaffected foot behind												
12 weeks prior to treatment							1.0	0.0	1.0	7.0	4.0	0.0
immediately before treatment	30.0	2.0	0.0	0.0	4.0	7.0	9.2 (820%)	0.0	4.3 (330%)	4.0 (-43%)	13.0 (225%)	0.0
after 4 weeks treatment (CT)							30.0 (2900%)	3.1	3.0 (200%)	30.0 (329%)	3.0 (-25%)	3.3
after 12 weeks treatment (CT)	24.3 (-19%)	30.0 #####	2.3	1.0	3.0 (-25%)	6.0 (-14%)	30.0 (2900%)	2.5	2.0 (100%)	20.0 (186%)	2.0 (-50%)	1.0
after 26/38 week home treatm	30.0 (0%)	nd	nd	0.0	2.7 (-33%)	3.9 (-44%)	30.0 (2900%)	nd	10.7 (972%)	30.0 (329%)	3.4 (-15%)	3.2
SLS (seconds)												
affected foot raised												
12 weeks prior to treatment							8.9	0.0	0.0	1.0	2.0	2.0
immediately before treatment	6.0	2.0	5.0	0.0	8.0	1.0	2.0 (-78%)	0.0	1.1	3.1 (210%)	2.0 (0%)	1.0 (-50%)
after 4 weeks treatment (CT)							30.0 (237%)	0.1	1.3	1.6 (60%)	0.0	1.0 (-50%)
after 12 weeks treatment (CT)	2.6 (-57%)	14.0 (600%)	0.0	0.0	0.0	2.0 (100%)	10.0 (12%)	0.0	1.6	5.4 (440%)	0.0	0.0
after 26/38 week home treatm	3.9 (-35%)	nd	nd		5.4 (-32%)	1.9 (90%)	23.2 (161%)	nd	5.0	2.1 (110%)	nd	nd
unaffected foot raised												
12 weeks prior to treatment							4.9	0.0	0.0	1.0	1.0	1.0
immediately before treatment	5.0	2.0	3.0	1.0	3.0	2.2	12.0 (145%)	0.0	2.1	3.1 (210%)	2.0 (100%)	0.7 (-30%)
after 4 weeks treatment (CT)							6.7 (37%)	0.1	0.1	1.6 (60%)	0.0	0.0
after 12 weeks treatment (CT)	2.4 (-52%)	2.7 (35%)	0.0	12.3 (1130%)	0.0	1.0 (-55%)	26.0 (431%)	0.0	1.7	5.4 (440%)	0.0	0.0
after 26/38 week home treatm	18.9 (278%)	nd	nd		30.0 (900%)	30.0 (1264%)	30.0 (512%)	nd	5.0	2.1 (110%)	nd	nd
WALK SPEED (metres/second)												
12 weeks prior to treatment							1.22	1.03	1.62	1.20	1.33	0.76
immediately before treatment	1.00	0.86	0.57	1.03	1.33	1.20	1.76 (44%)	1.54 (50%)	1.88 (16%)	1.94 (61%)	1.90 (43%)	1.50 (98%)
after 4 weeks treatment (CT)							1.94 (58%)	1.62 (58%)	2.00 (23%)	1.94 (61%)	2.04 (53%)	1.55 (104%)
after 12 weeks treatment (CT)	1.54 (54%)	1.62 (89%)	0.79 (39%)	1.67 (61%)	1.94 (45%)	1.71 (43%)	1.94 (58%)	1.60 (56%)	2.21 (36%)	1.94 (61%)	1.96 (47%)	1.50 (98%)
after 26/38 week home treatm	1.72 (72%)	nd	nd	1.33 (29%)	1.75 (32%)	1.09 (-9%)	2.07 (69%)	1.69 (64%)	2.54 (57%)	1.93 (61%)	2.00 (50%)	1.54 (103%)
WALK STRIDE LENGTH (metres)												
12 weeks prior to treatment							0.5	0.5	0.5	0.6	0.6	0.5
immediately before treatment	0.5	0.5	0.4	0.5	0.6	0.5	0.6 (20%)	0.7 (33%)	0.8 (38%)	0.9 (43%)	0.6 (0%)	0.7 (33%)
after 4 weeks treatment (CT)							0.4 (-20%)	0.8 (50%)	0.7 (22%)	0.9 (43%)	0.8 (25%)	0.7 (33%)
after 12 weeks treatment (CT)	0.7 (22%)	0.5 (18%)	0.5 (8%)	0.7 (33%)	0.5 (-23%)	0.8 (38%)	0.7 (33%)	0.7 (33%)	0.8 (38%)	0.9 (43%)	0.8 (25%)	0.7 (33%)
after 26/38 week home treatm	0.8 (38%)	nd	nd	0.6 (20%)	0.8 (25%)	0.7 (22%)	0.8 (50%)	0.7 (33%)	0.8 (38%)	0.8 (25%)	0.8 (25%)	0.8 (50%)
TUG (seconds)												
12 weeks prior to treatment							7.9	9.7	6.8	7.6	7.8	13.8
immediately before treatment	10.2	8.0	18.0	11.0	6.5	7.5	7.4 (6%)	8.5 (12%)	6.5 (4%)	7.3 (4%)	6.7 (14%)	9.3 (33%)
after 4 weeks treatment (CT)							6.4 (19%)	7.4 (24%)	6.3 (7%)	6.6 (13%)	6.5 (17%)	7.9 (43%)
after 12 weeks treatment (CT)	8.4 (18%)	7.1 (11%)	15.5 (14%)	8.5 (23%)	5.2 (20%)	6.6 (12%)	6.6 (16%)	7.6 (22%)	5.9 (13%)	7.1 (6%)	6.3 (19%)	7.6 (45%)
after 26/38 week home treatm	8.1 (21%)	nd	nd	9.9 (10%)	6.0 (7%)	5.8 (23%)	6.6 (16%)	8.0 (18%)	6.3 (7%)	6.6 (13%)	5.9 (24%)	7.9 (43%)
TUG MOTOR (seconds)												
12 weeks prior to treatment							8.8	9.0	6.9	7.6	8.3	11.8
immediately before treatment	10.9	8.2	17.7	10.6	7.1	7.2	8.2 (7%)	8.1 (10%)	6.5 (6%)	8.3 (-9%)	6.4 (23%)	9.1 (23%)
after 4 weeks treatment (CT)							7.4 (16%)	7.2 (20%)	6.6 (4%)	6.9 (9%)	6.4 (23%)	8.3 (30%)
after 12 weeks treatment (CT)	8.8 (19%)	8.2 (0%)	16.5 (7%)	9.3 (12%)	6.6 (7%)	7.0 (3%)	6.4 (27%)	8.5 (6%)	6.3 (9%)	7.1 (7%)	6.6 (20%)	8.1 (31%)
after 26/38 week home treatm	8.4 (23%)	nd	nd	13.3 (-26%)	6.1 (14%)	6.4 (11%)	6.0 (32%)	9.2 (-2%)	7.0 (-1%)	6.8 (10%)	5.8 (30%)	8.4 (29%)
TUG COGNITIVE (seconds)												
12 weeks prior to treatment							10.3	10.6	7.2	8.7	8.8	13.8
immediately before treatment	12.0	10.4	23.7	10.5	6.0	7.6	7.5 (27%)	8.8 (17%)	7.3 (-1%)	7.5 (14%)	6.7 (24%)	9.0 (35%)
after 4 weeks treatment (CT)							7.2 (30%)	8.2 (23%)	6.7 (7%)	6.6 (24%)	6.2 (30%)	8.7 (37%)
after 12 weeks treatment (CT)	9.3 (23%)	6.9 (34%)	18.2 (23%)	9.3 (11%)	5.2 (14%)	6.8 (11%)	6.3 (39%)	8.9 (16%)	6.4 (11%)	6.8 (22%)	6.8 (23%)	8.1 (41%)
after 26/38 week home treatm	8.8 (26%)	nd	nd	9.8 (6%)	5.2 (13%)	5.9 (22%)	6.7 (35%)	9.5 (11%)	6.5 (10%)	6.4 (27%)	6.6 (25%)	8.8 (36%)
MoCA score												
12 weeks prior to treatment							26	28	27	26	24	21
immediately before treatment	24	26	26	28	27	24	29 (12%)	29 (4%)	27 (0%)	26 (0%)	28 (17%)	24 (14%)
after 4 weeks treatment (CT)							28 (8%)	30 (7%)	28 (4%)	26 (0%)	28 (17%)	25 (19%)
after 12 weeks treatment (CT)	25 (4%)	26 (0%)	28 (8%)	28 (0%)	27 (0%)	29 (21%)	29 (12%)	30 (7%)	27 (0%)	27 (4%)	29 (21%)	29 (38%)
after 26/38 week home treatm	29 (21%)	29 (12%)	nd	30 (7%)	28.7 (6%)	30 (24%)	30 (15%)	30 (7%)	30 (11%)	28.7 (10%)	30 (25%)	nd

NHPT = nine-hole peg test

TS = tandem stance (eyes closed)

SLS = single leg stance (eyes closed)

TUG = timed up-and-go

MoCA = Montreal Cognitive Assessment

number in brackets is the percentage improvement (positive value) or decline (negative value) in an outcome measure